Clinical Trials
43 trialsNCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
NCT03620643 2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2 Completed
NCT02075840 2025-07-25
ALEX
Hoffmann-La Roche
Phase 3 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT00828919 2024-12-03
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Pfizer
Phase NA Completed
NCT01970865 2024-08-12
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Pfizer
Phase 1/2 Completed
NCT02679170 2024-08-09
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Pfizer
Completed
NCT01712217 2024-08-02
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01979536 2024-04-30
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02034981 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02223819 2023-12-06
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Columbia University
Phase 2 Completed
NCT01744652 2023-06-07
Dasatinib and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed
NCT02419287 2023-03-06
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
University of Milano Bicocca
Phase 2 Completed
NCT00585195 2023-02-08
PROFILE 1001
Pfizer
Phase 1 Completed
NCT02183870 2022-06-16
EUCROSS
University of Cologne
Phase 2 Completed
NCT02270034 2022-03-10
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
Phase 1 Completed
NCT03088930 2022-02-11
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02207504 2022-01-06
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01945021 2021-02-21
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Pfizer
Phase 2 Completed
NCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01639001 2020-12-08
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
Pfizer
Phase 3 Completed
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00939770 2020-06-09
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1/2 Completed
NCT02745691 2019-12-13
Psychometric Properties of the EORTC QLQ-LC29
University Hospital Regensburg
Completed
NCT01597258 2019-09-13
Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT01644773 2019-03-22
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01576406 2018-10-25
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Pfizer
Phase 1 Completed
NCT01998126 2018-04-02
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
University of Utah
Phase 1 Completed
NCT02435108 2017-02-17
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT00932451 2017-01-13
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Pfizer
Phase 2 Completed
NCT00932893 2017-01-02
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Pfizer
Phase 3 Completed
NCT00965731 2015-10-28
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Pfizer
Phase 1 Completed
NCT01121575 2015-10-28
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Pfizer
Phase 1 Completed